Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial

Abstract

The primary end point (independently assessed DFS) was not met despite favorable OS seen with <i>nab</i>-paclitaxel + gemcitabine.